To examine the effects of IFN-γ, a clinical trial (NCT03112590) aimed at testing a combination of IFN-γ with paclitaxel, trastuzumab, and pertuzumab in HER2+ BC was initiated. The gene discussed is ERBB2; the disease is breast cancer.